Artificial intelligence for ophthalmic drug discovery and development: Capabilities, applications, and challenges

Siddharth Gandhi,Michael Balas
DOI: https://doi.org/10.36922/aih.3341
2024-07-22
Abstract:The integration of artificial intelligence (AI) into ophthalmic drug discovery and development presents transformative opportunities to address the inherent complexities and challenges of creating targeted therapies for eye diseases. The ability of AI to process vast datasets can facilitate the discovery of novel drug candidates, improve predictions of drug efficacy and safety, and streamline the drug development pipeline. Applications can range from enhancing target identification and compound screening to refining predictive toxicology. However, challenges such as data limitations, computational demands, model interpretability, and ethical considerations remain. Despite these hurdles, the integration of AI with emerging technologies and its potential to optimize clinical trials signifies a new era of innovation in ophthalmology, emphasizing its critical role in addressing current challenges and advancing therapeutic development. In this paper, we explore the role of AI in ophthalmic drug discovery, highlighting its potential to address critical challenges in the field and delineating its impact across various stages of drug development.
What problem does this paper attempt to address?